INCYTE CORP

Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’

CNBC final trades: Pros picked Schwab, Cleveland-Cliffs, UnitedHealth and Incyte; shares posted mixed moves Wednesday.

Incyte Appoints Suketu (Suky) Upadhyay As Executive Vice President And CFO Effective May 4, 2026

Assessment of the Rheumatoid Arthritis Market 2026-2036 Featuring Rise Therapeutics, Taiho Pharmaceutical, Abbvie, Eli Lilly/Incyte, and AstraZeneca

Unmet needs in refractory patients, tolerability, access, adherence, and flare prevention create room for innovationDublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. Rheumatoid Arthritis Market Forecast to Reach New Growth Milestones Through 2036, Driven by Targeted Therapies and Expanding Patient Demand The report provides a comprehensive analysis of the rheumatoid

Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks

In a recent interview on CNBC’s Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) as two of his “Best Stocks in the Market.” Brown said he wanted to focus on stocks that had “nothing to do” with the AI and data-center spending theme. “We wanted to […]

Here Are Monday’s Best Wall Street Analyst Research Calls: Accenture, Apple, Boyd Gaming, BWX Technologies, Conoco-Phillips, Estee Lauder, Hut 8, Incyte, SpaceX, and More

Pre-Market Stock Futures: Futures are trading mixed as we prepare to finish the last full week of the second quarter. We finished a wild holiday-shortened trading week last Thursday, as Friday was the federal Juneteenth holiday, and all major indices rebounded smartly from the Federal Reserve-induced sell-off on Wednesday. Details of the signed memorandum of ... Here Are Monday’s Best Wall Street Analyst Research Calls: Accenture, Apple, Boyd Gaming, BWX Technologies, Conoco-Phillips, Estee Laud

Lilly scores early positive data for new JAK drug

Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.